Goldman Sachs upgraded Beta Bionics (BBNX) to Buy from Neutral with a price target of $26, up from $18, which offers 31% upside. The firm’s analysis of the diabetes technology market shows sustained growth and profitability for Beta. The company should experience the most upside within the renewal segment of the market, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX: